Keywords
Cyclin d1, Cell proliferation,Oral potential malignant disorder, Oral squamous cell carcinoma, Immunohistochemistry
This article is included in the Datta Meghe Institute of Higher Education and Research collection.
Cyclin d1, Cell proliferation,Oral potential malignant disorder, Oral squamous cell carcinoma, Immunohistochemistry
Oral squamous cell carcinoma (OSCC) is a malignant epithelial tumor with poor prognosis. OSCC is one of the top causes of death in India and Southeast Asia.1 Oral squamous cell carcinoma caused due to chewing tobacco, such as panmasala, gutkha, gudakhu, khaini, and other products composed of tobacco.2,3 Patients with middle-aged to older ages typically affected by OSCC.4 OSCC have a high rate of proliferation of malignant epithelial cells. The prognosis of OSCC depends on recommended surgical margin.
In the surgical margin, the epithelial cells may be altered by field cancerization. There is an increase in the proliferation of epithelial cells in OSCC which is control by cell cycle regulators like Cyclin D1.5
Cyclin control the orderly phases of the cells through the G1, S, G2, and M phases of the cell cycle.6,7 It plays a role in cell cycle induction, transcriptional control, and DNA damage-induced death.2 (CCND1) Cyclin D1, 11q13 location of chromosomes, carries the cell cycle from the G1 to the S phase by encoding a vital cell cycle regulating protein.8‐10 The control of the cell cycle is facilitated by Cyclin D1, proto-oncogenes and an enzyme known as Cylin-dependent kinase 4 (CDK4). It also interacts with other transcriptional factor (TFs) and controls the activity of transcriptional cofactors.4 Lack of regulation of the cell cycle mechanism is an essential phase in the carcinogenic change. Cyclin D1 is linked to a poor prognosis for patients, including aggressive malignancies, recurrence, protracted remission, etc.3
TRIAL DESIGN: Retrospective study.
This study will be conducted in the Department of Oral Pathology and Microbiology, Sharad Pawar Dental College in collaboration with Central Research Laboratory, Datta Meghe Institute of Higher Education & Reasearch, Sawangi (Meghe) Wardha.
Inclusion criteria
• Paraffin embedded tissue sections of well differentiated squamous cell carcinoma (WDSCC), moderately differentiated squamous cell carcinoma (MDSCC), poorly differentiated squamous cell carcinoma (PDSCC) histopathologically, their surgical margins and normal oral mucosa (NOM) will be retrieved from archival of department.
• 80 surgically treated patients who have been clinically and histopathologically diagnosed with OSCC.
• Recorded demographic data of clinical presentation, habits and its duration, histopathological findings, operative details will be noted in detail from department.
• Follow-up data for 2-3 years of disease-free survival.
Exclusion criteria
All tissue sections will be proceeded for Cyclin D1 IHC. After that, a light microscopic evaluation of Cyclin D1 expression was classified as weak (scoring 1-4), moderate (score 5-8), or strong based on a final expression score that was obtained by multiplying the labelling an index score by the intensity score (score 9–12).
The present study will find the immunohistochemical expression of cyclin D1 tumor tissue and surgical margins of OSCC, in order to evaluate the prognosis of OSCC.
There will be a variation in the immunoexpression of Cyclin D1 among different grades of oral squamous cell carcinoma, its surgical margin and normal oral mucosa.
Considering the prevalence of OSCC as 70.7% in the outpatient department of Oral Pathology and Microbiology, using a single proportion formula, the sample size is calculated via the expression below.11
Where,
Z21-α/2 - The level of significance at 5 %
i.e. 95 % confidence interval =1.96
p - Sample demonstrating +ve Cycline D1 expressions in tiny groups of cells in the basal layer of the
epithelium = 70.7% = 0.707
E - Errors of margins = 10 % = 0.10
n = 1.962x 0.707 x (1-0.707) /0.102
n = 80
Formula reference - Angadi PV, Krishnapillai R. Cyclin D1 expression in OSCC and verrucous carcinoma: correlation with histological differentiation. OS, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology. 2007 Mar 1;103(3):e30-5
A paraffin block having suitable mass of tumor and acceptable amount of normal tissue is selected. On Poly-L-Lysinecoated slides, sections of having thickness of three micrometers are cut & placed. For De-paraffinization, sections are placed in the xylene solution. Sections are rehydrated by subjecting them to descending concentrations of alcohol (70-100%). In order to wash sections, tap water is used. Washing time for sections in distilled water is 60 seconds. After washing all the sections are transferred to Coplin’s jar containing the retrieval buffer solution. The solution which is used for Antigen retrieval is composed of 30 ml of retrieval solution in 1500 mili-liters of distilled water for fifteen to twenty minutes in the pressure cooker. Cooling is done at room temperature.
Sections are dipped once in distilled water. Sections are washed with Tris buffer solution for at least 5 minutes at room temperature. This step is repeated thrice. For peroxidase blocking a mixture of “3,5 Hydrogen Peroxide and Methanol” is used for thirty minutes. Tris buffer solution is used for washing the sections 3 times for 5 minutes each. Primary antibody cyclin D1 is applied at room temperature for 1 hour. Envision technique is performed by utilizing a labelled polymer for 30 minutes at room temperature. For washing the sections tris buffer solution is used thrice for five minutes.
The application of “DAB (3,3’-diaminobenzidine)” substrate is done for fifty to twenty minutes. The working DAB solution is comprised of following –one millilitre of DAB buffer & twenty five microliters of “DAB concentrate”. This time, washing of sections is done by Tris buffer, for 15-20 minutes. Sections are cleaned in distilled water. For counter staining Mayer’s hematoxylin is used, which is done for five minutes. Again, the washing of sections is done under tap water and then dried. Once the sections are dried; mounte in DPX. After that a microscopic examination is done. Calculations will be made to determine the median percentage per slide (labelling index) and the proportion of IHC positive tumour cells per hot spot. Labelling indices of 1-35%, 36-70%, and 71-100%, respectively, each received a score of 1, 2, or 3. According to their microscopic appearance, Cyclin D1 immunostaining intensity will be assigning each a score of 0, 1, 2, or 3 will indicate whether it is weak, intermediate, or strong. Cyclin D1 expression was classified as weak (scoring 1-4), moderate (score 5-8), or strong based on a final expression score that was obtained by multiplying the labelling index score by the intensity score (score 9–12). We will tabulate and do the necessary statistical analysis on all relevant clinical, histopathological, and immunohistochemical information that we will gather.
King Y. Lam at el., (2000) examined how Cyclin D1 relates to the clinical and pathological characteristics of OSCC. They found that Cyclin D1 expressions were present in 63% of OSCC; that was typically modest but more commonly positive in high-grade lesions. Radiation therapy had no effect on either Cyclin D1's expression. Expression was unrelated to patient age, gender, survival, tumour stage, or patient demographics. Patients with the floor of the mouth, gingiva, oropharynx, and palate squamous cell carcinomas had overexpressed Cyclin D1. The researchers came to the conclusion that Cyclin D1 was often expressed in OSCC, connected to the high grade of tumours, and was not similar in different regions of the oral cavity, indicating diverse tumour biology of carcinoma from theis area.
R Miyamoto et al., in 2003 showed that the relationship among Cyclin D1 (CCND1) extension and over expressions in OSCCs were examined, and the predictive validity of Fluorescence in-situ Hybridization (FISH) on Cyclin D1 (CCND1) amplification with immunohistochemical over expression in fine-needle aspiration (FNA) samples was established. In every instance where CCND1 was amplified, they noticed CCND1 overexpression. While 14 of the 28 instances 50.0% that did not show such intensification showed CCND1 overexpression. They noticed insignificant The statistical correspondence among CCND1 over-expression and reduced endurance as well as the independent prognostic significance of CCND1 amplification and nodal status. They came to the conclusion that there is a need to look into the additional routes besides CCND1 amplification that control CCND1 expression. They also came to the conclusion that in OSCCs, CCND1 intensification is a more accurate analytical predictor than CCND1 over expression.
S Saawarn et al., in Cyclin D1's immunohistochemistry reactivity and expression, as well as their relationships to the location, clinically staged, and histological discrimination of OSCC, were examined in 2011. (OSCC). 45% of people showed expression of cyclin D1 of Oral SCC cases, although it was unrelated to the site or clinical stage. Moreover, they find a statistical significance link among the highest expression being detected in well-differentiated squamous cell carcinomas, followed by MDSCC and PDSCC. They came to the conclusion that as differentiation rises, Cyclin D1 expression does as well.
Y OHNISHI et al., in 2014 immunohistochemically examined the relationship among cyclin D1 expression and ki-67 expressions in oral Squamous CC and connected their expression among cells segregation, cells abundance, and metastasis. They discovered the expression of Cyclin D1 and Ki-67 in the nucleus of all 35 Squamous CC tissue, although they did not discover a connection between oral SCC differentiation and Cyclin D1 protein expression. Also, they discovered that 90% of metastatic foci had significant Cyclin D1 expression, in contrast to metastatic foci treated with preoperative adjuvant therapy, which had poor expression. Moreover, Cyclin D1 and Ki-67 were found in the basal to suprabasal cell layer of the WD oral SCC, while the highly-differentiated region also contained cyclin D1-positive and Ki-67-negative cells. Also, they proposed that in WD oral SCC, Cyclin D1 protein expression is essential for the growth and differentiation of cells.
Ethical approval received from Datta Meghe Institute of Higher Education and Research, Sawangi, Wardha.
IEC reference number- DMIHER (DU)/IEC/2023/842.
Informed written consent was obtained from the patient before surgery and before the before the write-up of the protocol as per the data requirement of this study.
No data associated with this study.
Zenodo, STROBE checklist for cross sectional study.
DOI - 10.5281/zenodo.7874225.
Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the rationale for, and objectives of, the study clearly described?
No
Is the study design appropriate for the research question?
No
Are sufficient details of the methods provided to allow replication by others?
No
Are the datasets clearly presented in a useable and accessible format?
Partly
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Oral and Maxillofacial Pathology, Oral Cancer, Lymph node metastasis in Oral cancer, micro RNA in Saliva, Oral exfoliative cytology
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | |
---|---|
1 | |
Version 1 01 Sep 23 |
read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)